This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0879

Transcranial magnetic stimulation in obsessive-compulsive disorder

TRANSCRANIAL MAGNETIC STIMULATION IN OBSESSIVE–COMPULSIVE DISORDER

Transcranial magnetic stimulation significantly reduces symptom severity compared with sham stimulation, particularly in treatment-resistant obsessive-compulsive disorder, with reported treatment response rates ranging from 30% to 60%.

The aim of the review was to summarize current evidence on the efficacy and neurobiological effects of transcranial magnetic stimulation (TMS) in obsessive-compulsive disorder (OCD). As its rationale, the poster notes that a substantial proportion of patients remain symptomatic despite adequate pharmacological and psychotherapeutic treatment. It explains that TMS targets disrupted neural circuits in OCD and that magnetic pulses generate electrical currents in specific brain regions, modulating neural activity and network connectivity. The dorsolateral prefrontal cortex (DLPFC) is described as the most frequently targeted region in OCD. The neurobiological effects listed include modulation of cortico-striato-thalamo-cortical circuits, normalization of abnormal frontostriatal connectivity, neurotransmitter regulation, and neuroplasticity. The results section reports that numerous randomized controlled trials (RCTs) and meta-analyses support the benefits of TMS, particularly in treatment-resistant cases. It states that TMS significantly reduces OCD symptom severity compared with sham stimulation, that the most consistent results have been obtained with high-frequency (above 10 Hz) rTMS applied over the left DLPFC, that response rates in treatment-resistant OCD range from 30% to 60%, and that TMS is well tolerated, with mild and transient side effects such as headache. The poster concludes that TMS is a promising, noninvasive option for patients who do not respond adequately to conventional treatments, and that large-scale, longitudinal studies are needed to clarify protocols, targets, and long-term efficacy and safety. The poster does not report the number of included studies, the sample size, or a pooled effect size.

All WCP 2026 summaries